Neurosurgical resection of brain metastases followed by stereotactic radiation can lead to pachymeningeal seeding outside of the stereotactic radiation field, according to findings reported in JAMA Oncology.
The outcomes of patients with a first recurrence of WHO grade II or III glioma without the 1p/19q co-deletion are not improved when bevacizumab is added to the standard of care temozolomide, suggest phase II trial findings.
A recombinant nonpathogenic polio–rhinovirus chimera has demonstrated promising tolerability and efficacy in patients with recurrent malignant glioma in a phase I trial.
Treatment with DNX-2401, a tumor-selective adenovirus, can lead to “dramatic responses” and long-term survival in some patients with recurrent malignant glioma, say researchers who conducted a phase I study.
Adding bevacizumab to radiotherapy plus temozolomide does not improve event-free survival in children with newly diagnosed high-grade glioma, trial findings show.
Adding tumor-treating fields to standard treatment with temozolomide does not negatively affect health-related quality of life in patients with newly diagnosed glioblastoma, an analysis of EF-14 data shows.